Three or five years of adjuvant imatinib for the treatment of patients with operable GIST with a high risk of relapse: A randomized phase III study. Read More

Genotype-guided Personalised Fluoropyrimidine Dosing: Feasibility and Implementation Read More

Lignocaine Infusion in Colorectal Cancer Patient Immune Cells (LICPIC Study) Read More

Neoadjuvant Immune-Chemo-Radiotherapy in operable oesophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab – a Trial assessing feasibility and preliminary Efficacy Read More

This study aims to demonstrate that a chemotherapy decision incorporating ctDNA results in addition to standard pathologic risk assessment will reduce the number of patients receiving adjuvant chemotherapy. Read More

This study aims to demonstrate that a ctDNA informed approach to chemotherapy, following surgery for localised pancreatic cancer, could lead to a reduction in the proportion of patients with detectable ctDNA after completion of treatment compared to standard of care. Read More

The purpose of the DYNAMIC-III study is to determine that a chemotherapy decision based on the presence or absence of circulating tumour DNA after surgery for stage III colorectal cancer, will be more effective than standard of care treatment as measured by how many patients remain cancer free at 3 years. Read More

The aim of ALT GIST is to determine whether an alternating treatment approach - using Imatinib and Regorafenib - improves disease control in patients with advanced (metastatic) gastrointestinal stromal tumours. Read More

The aim of ACTICCA-1 is to determine whether treating patients with chemotherapy following surgery for cancer of the biliary tract helps to reduce cancer recurrence. Read More

The purpose of TOPGEAR is to investigate the benefit of adding radiation (chemoradiotherapy) to chemotherapy and surgery to treat and improve the overall survival in patients undergoing surgery for resectable stomach cancer. Read More

The aim of NABNEC is to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with the current standard chemotherapy treatment plan (carboplatin plus etoposide) for advanced gastrointestinal neuroendocrine carcinomas (NECs). Read More

The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer. Read More

The purpose of INTEGRATE II is to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma (AGOC). Read More